LONDON - Shares in Pharmagene plc dropped by one-quarter when the company announced its lead product, PGN0052, failed in a Phase IIa trial in cystic fibrosis and the company warned that 2004 revenues from its drug discovery services would be lower than 2003. (BioWorld International) Read More
